| Literature DB >> 23984363 |
Marcello Pilia1, Teja Guda, Mark Appleford.
Abstract
The need for a suitable tissue-engineered scaffold that can be used to heal load-bearing segmental bone defects (SBDs) is both immediate and increasing. During the past 30 years, various ceramic and polymer scaffolds have been investigated for this application. More recently, while composite scaffolds built using a combination of ceramics and polymeric materials are being investigated in a greater number, very few products have progressed from laboratory benchtop studies to preclinical testing in animals. This review is based on an exhaustive literature search of various composite scaffolds designed to serve as bone regenerative therapies. We analyzed the benefits and drawbacks of different composite scaffold manufacturing techniques, the properties of commonly used ceramics and polymers, and the properties of currently investigated synthetic composite grafts. To follow, a comprehensive review of in vivo models used to test composite scaffolds in SBDs is detailed to serve as a guide to design appropriate translational studies and to identify the challenges that need to be overcome in scaffold design for successful translation. This includes selecting the animal type, determining the anatomical location within the animals, choosing the correct study duration, and finally, an overview of scaffold performance assessment.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23984363 PMCID: PMC3745947 DOI: 10.1155/2013/458253
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Stages of the bone-healing cascade. Adapted into a table form from [69].
| Early inflammatory stage |
|
|
| |
|
| |
|
| |
|
| |
| Repair stage |
|
|
| |
|
| |
|
| |
|
| |
|
| |
| Remodeling stage |
|
Different causes of SBDs and consequences of untreated SBDs.
| Causes of SBDs | |
| Trauma injuries |
|
|
| |
|
| |
| Diseases | These include bone cancer (requiring tumor resection and reconstruction), osteoporosis, osteoarthritis, generic infections, congenital deformity corrections, and pathological degenerative bone destruction. The commonality among these diseases is that the bone is either abnormally weak or needs to be removed to prevent spreading of the disease. As a result, large segments of bone are missing or are surgically removed and need to be replaced. |
|
| |
| Complications from untreated SBDs | |
| Malunion | The two fractured bone ends are able to bridge, although they are not symmetrically aligned. As a result, the new bone is still susceptible to fracture. This is commonly seen in undiagnosed/untreated fractures and leads to loss of bone function. |
|
| |
| Nonunion (pseudarthrosis) | The two fractured bone ends are not able to heal, and no bridging occurs between them. This is seen in critical defects. Another case of nonunion is observed when there is too much movement between the bone ends (insufficient surgical fixation) and the callus is never able to ossify and harden. In many cases, surgical intervention is needed to resolve the problem and avoid further loss of bone function. |
Figure 1(a) Radiograph of open tibial fracture with segmental bone loss as a result of trauma injury. (b) Radiograph of the damaged tibia after intramedullary nail and internal fixation at the extremities. The defect is filled with cement spacer that had been previously impregnated with antibiotic. (c) Radiograph of the defect after 3 and (d) 4 months. Bone healing never occurred, and the fracture is considered a nonunion. Printed with permission from Dr. Steve Morgan [37].
Figure 2Diagram showing material (top) and biological (bottom) properties of ultimate regenerative bone scaffolds. It is necessary for engineered scaffolds to have both of these properties to promote bone growth. One class of properties alone is not sufficient to promote bone growth in a timely manner. Data originated from [21, 23, 24, 28, 38–42].
Bone tissue-engineered scaffold requirements.
| Biological properties |
|
|
| |
|
| |
|
| |
|
| |
|
| |
| Material properties |
|
|
| |
|
| |
|
| |
Importance of mechanical stability in segmental bone defects.
| Mechanical properties | Ultimate strength of cortical bone ranges between 100 and 230 MPa. Any scaffold that does not match this strength requires surgical fixation to prevent crushing/failure of the implant. Because bone is a mechanosensor organ, it is believed that a scaffold that is loaded cyclically will benefit from faster healing time. |
|
| |
| Surgical fixation | Current bone tissue-engineered scaffolds require surgical fixation of the fractured extremities to prevent movement between the bone endings. This allows for callus formation and ossification to occur. Surgical fixation devices include screws, hardware, and intramedullary nails. They are often made of metals, specifically titanium or titanium alloys. |
|
| |
| Stress shielding | Condition caused by the use of surgical fixation devices in load-bearing bones. Because metals have a higher modulus and compression strength, they support nearly all of the weight. In return, the fractured bone does not sense a significant change in mechanical activity, leading to a loss in bone density over time. |
Significant physical properties of several of the most common bioceramics used as biomaterials [70].
| Material | Density (g/cm3) | Tensile strength (MPa) | Compressive strength (MPa) | Modulus (GPa) | Fracture toughness | Hardness (Knoop) | Mass fraction | Fracture surface energy (J/m2) | Poisson's ratio | Thermal conductivity |
|---|---|---|---|---|---|---|---|---|---|---|
| Hydroxyapatite | 3.1 | 40–300 | 300–900 | 80–120 | 0.6–1.0 | 400–4500 | 11 | 2.3–20 | 0.28 | N/A |
| Tricalcium phosphate | 3.14 | 40–120 | 450–650 | 90–120 | 1.2 | N/A | 14-15 | 6.3–8.1 | N/A | N/A |
| Bioglasses | 1.8–2.9 | 20–350 | 800–1200 | 40–140 | ~2 | 4000–5000 | 0–14 | 14–50 | 0.21–0.24 | 1.5–3.6 |
| Wollastonite glass ceramic | 3.07 | 215 | 1080 | 118 | 2 | N/A | N/A | N/A | N/A | N/A |
| SiO2 glass | 2.2 | 70–120 | N/A | ~70 | 0.7–0.8 | 7000–7500 | 0.6 | 3.5–4.6 | 0.17 | 1.5 |
| Al2O3 | 3.85–3.99 | 270–500 | 3000–5000 | 380–410 | 3–6 | 15000–20000 | 6–9 | 7.6–30 | 0.27 | 30 |
| Zirconia ceramics | 5.6–5.89 | 500–650 | 1850 | 195–210 | 5–8 | ~17000 | 9.8 | 160–350 | 0.27 | 4.11 |
| Si3N4 | 3.18 | 600–850 | 500–2500 | 300–320 | 3.5–8.0 | ~22000 | 3.2 | 20–100 | 0.27 | 10–25 |
| Silicon carbide | 3.10–3.21 | 250–600 | ~650 | 350–450 | 3–6 | ~27000 | 4.3–5.5 | 22–40 | 0.24 | 100–150 |
| Graphite | 1.5–2.25 | 5.6–25 | 35–80 | 3.5–12 | 1.9–3.5 | N/A | 1–3 | ~500 | 0.3 | 120–180 |
| Multiceramics | 1.5–2.2 | 200–700 | 330–360 | 25–40 | N/A | N/A | 1–10 | N/A | 0.3 | 2.5–420 |
| Carbon fiber | 1.5–1.8 | 400–5000 | 330–360 | 200–700 | N/A | N/A | N/A | N/A | N/A | N/A |
| Glassy carbon | 1.4–1.6 | 150–250 | ~690 | 25–40 | N/A | 8200 | 2.2–3.2 | N/A | N/A | N/A |
Significant physical properties of several of the most common polymers [71].
| Polymer | Glass melting point Tm | Glass transition point | Biodegradation time (months) | Compressive strength | Tensile strength | Modulus |
|---|---|---|---|---|---|---|
| PE | 0.1–1.0 | 0.4–4.0 | 170 | |||
| PMMA | 3.5 | 1.5 | 160 | |||
| PDLLA | Amorphous | 55–60 | 12–16 | Pellet: 150* | Film or disk: 29–35 | Film or disk: 1.9–2.4 |
| PLLA | 173–178 | 60–65 | >24 | Pellet: 120* | Film or disk: 28–50 | Film or disk: 1.2–3.0 |
| PGA | 225–230 | 35–40 | 6–12 | Fiber: 340–920 | Fiber: 7–14 | |
| PLGA | Amorphous | 45–55 | Adjustable: 1–12 | 41.4–55.2 | 1.4–2.8 | |
| PPF | N/A | Bulk | 30* | 2 | ||
| PCL | 58 | −72 | >24 | |||
| PHA and blends | 120–177 | −2 to 4 | Bulk | 20–43 | ||
| Poly(anhydrides) | 150–200 | Surface | 40* | 25–27 | 0.14–1.4 | |
| Poly(ortho esters) | 30–100 | Surface | 16* | 2.5–4.4 | ||
| Polyphosphazene | −66 to 50 | 242 | Surface |
(a)
| Author, year | Ceramic material | Polymeric material | Animal choice | Anatomical choice | Length of study | Time points | Sample size | Defect size | Scaffold size | Control |
|---|---|---|---|---|---|---|---|---|---|---|
|
Cao and Kuboyama, 2010 [ |
| PGA | Sprague-Dawley rats | Femur; Medial epicondyle | 12 weeks | 0, 14, 30, and 90 days | 5/time points/group | 3 mm diameter; 2 mm depth | N/A | (+) HAp |
|
| ||||||||||
|
Chu et al., 2007 [ | TCP | PPF | Long Evans rats | Femur | 15 weeks | 6 and 15 weeks | 4 or 7/time point/group | 5 mm | OD: 4 mm—ID: 2 mm; Height 5 mm | No BMP |
|
| ||||||||||
|
Jegoux et al., 2008 [ | BCaP | Collagen | New Zealand white rabbit and beagle dogs | Femur | 18 weeks | 18 weeks | 6 rabbits, 6 dogs | 20 mm | 5 × 5 × 5 mm | |
|
| ||||||||||
|
Guda et al., 2011 [ | HAp | New Zealand white rabbit | Radial diaphysis | 8 weeks | 4 and 8 weeks | 12/time point/group | 10 mm | (+) autograft | ||
|
| ||||||||||
|
Ignatius et al., 2001 [ |
| PLA | Merino sheep | Tibia | 8 weeks | 6, 12, and 24 months | 6/time point/group | N/A | 24 mm length, 14 mm wide, 6 mm thick | (+) TCP |
|
| ||||||||||
|
Jayabalan et al., 2010 [ | HAp | HT-PPFhm | Rabbit | Femur | 48 weeks | 12, 24, and 48 weeks | 2/time point | 4 mm diameter; 2 mm depth | N/A | (−) no implant |
|
| ||||||||||
|
Lickorish et al., 2007 [ | TTCP and DCPA | PLGA | Wistar rats | Femur | 2 weeks | 2 weeks | N/A | 2.3 mm diameter | 2 mm diameter | PLGA |
|
| ||||||||||
|
Rai et al., 2010 [ | TCP | PCL | CBH/Rnu rats | Femur | 3 weeks | 3 weeks | 6/time point | 8 mm | 8 mm high, 4 mm diameter | (−) non-seeded |
|
| ||||||||||
|
Xu et al., 2011 [ | Bioglass | Collagen-phosphatidylserine | Sprague-Dawley rats | Femur | 6 weeks | 3 day, 3 and 6 weeks | 3/time point/group | 3.5 mm diameter; | N/A | No phosphatidylserine |
(b)
| Author, year | Type of testing | Type of histology | Histological parameters analyzed |
| Mechanical testing |
|---|---|---|---|---|---|
|
Cao and Kuboyama, 2010 [ |
| Decalcified histology | Area of material in defect, new bone volume/total volume percent material biodegradation | Bone reformation | No |
|
| |||||
|
Chu et al., 2007 [ | Radiograph, | MMC histology | New bone formation | Callus and scaffold volumetric bone mineral density | Four-point bending |
|
| |||||
|
Jegoux et al., 2008 [ | Polarized Light; | Glycol methacrylate | Used thick histology sections for observation under poler | Bioceramic, newly formed bone at the center, and superior and inferior quarter of the implant | No |
|
| |||||
|
Guda et al., 2011 [ | Radiograph, | MMC histology | Mineralized bone, fibrous tissue | Bone regeneration patterns, bone density, bone growth profiles, and overall bone volume | Four-point bending |
|
| |||||
|
Ignatius et al., 2001 [ | Mechanical, histology | Undecalcified histology | New bone formation, new soft tissue formation, remaining implant components | No | Compression of 5 × 5 × 3 mm cubes |
|
| |||||
|
Jayabalan et al., 2010 [ | Histology | Resin histology | Foreign body giant cell, bone growth | No | No |
|
| |||||
|
Lickorish et al., 2007 [ | Histology | Decalcified histology | Fibrous tissue formation, bone ingrowth, foreign body reaction | No | No |
|
| |||||
|
Rai et al., 2010 [ | Radiograph, | Decalcified histology | Presence of fibroblasts, chondrocytes, woven bone | New bone formation | No |
|
| |||||
|
Xu et al., 2011 [ | Histology; radiography | Decalcified histology | Inflammatory reaction, new bone formation, scaffold resorption | No | No |